Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice. (Q42980686)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 May 2012

Language	Label	Description	Also known as
English	Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice.	scientific article published on 24 May 2012

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Recombinant retrovirus-derived virus-like particle-based vaccines induce hepatitis C virus-specific cellular and neutralizing immune responses in mice (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Hepatitis C virus

1 reference

based on heuristic

inferred from title

Bertrand Bellier

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

David Klatzmann

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Christophe Huret

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Delphine Desjardins

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Mathilde Miyalou

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Béatrice Levacher

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Martin Amadoudji Zin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Olivia Bonduelle

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Béhazine Combadière

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Charlotte Dalba

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

0 references

publication date

24 May 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

31

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1540-1547

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22634300%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Update on hepatitis C virus-specific immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

The role of neutralizing antibodies in hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Progress in the development of preventive and therapeutic vaccines for hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Intranasal DNA vaccination induces potent mucosal and systemic immune responses and cross-protective immunity against influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Replication-competent vectors and empty virus-like particles: new retroviral vector designs for cancer gene therapy or vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Increased Cytotoxic T-Lymphocyte Epitope Variant Cross-Recognition and Functional Avidity Are Associated with Hepatitis C Virus Clearance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Degree of cross-genotype reactivity of hepatitis C virus-specific CD8+ T cells directed against NS3.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Development of hepatitis C virus vaccines: challenges and progress.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

An effective HIV vaccine: A combination of humoral and cellular immunity?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.025

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42980686&oldid=1694396285"